The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

New antibody shows strong potential against pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Scientists at the Translational Genomics Research Institute, part of City of Hope, in collaboration with SIWA Therapeutics Inc., recently published results from a preclinical study that highlights the potential of SIWA318H, an advanced glycation end product-targeting antibody, for the treatment of pancreatic cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

City of Hope, Charles R. Drew University of Medicine and Science launch new educational research and training program

City of Hope and Charles R. Drew University of Medicine and Science, the only Historically Black Graduate Institution west of the Mississippi River and one of only four Historically Black Medical Schools, announced the launch of a new partnership to educate a more diverse workforce in specialized medicine through internships, curriculum, training, mentorships, joint research projects, and more.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account